GNH USA

Europe — EMA

Nipruss (Sodium Nitroprusside Dihydrate)

GNH USA supplies Nipruss (Sodium Nitroprusside), a vasodilator for hypertensive emergency, controlled hypotension during surgery, and acute heart failure

Sodium Nitroprusside Dihydrate

Request sourcing

1
Pack/s

What is Sodium Nitroprusside Dihydrate?

Sodium Nitroprusside Dihydrate, the active ingredient in Nipruss, is a vasodilator presented as an intravenous solution for intravenous use. It treats hypertensive emergencies, provides controlled hypotension during surgery, and assists in managing acute heart failure with severe hypertension.

GNH USA supplies Nipruss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

What is Sodium Nitroprusside Dihydrate used for?

Nipruss, a rapid‑acting vasodilator, is employed in critical cardiovascular settings.

Hypertensive emergency: rapid reduction of severe arterial pressure. Controlled hypotension during surgery: maintains target low blood pressure to minimise intra‑operative bleeding. Acute heart failure with severe hypertension: lowers afterload and improves cardiac output.

What are the side effects of Sodium Nitroprusside Dihydrate?

Sodium nitroprusside may cause a range of adverse reactions, varying from mild to life‑threatening.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional during infusion. - Flushing: transient skin warmth. - Excessive hypotension: sudden drop in blood pressure. - Tachycardia: reflex increase in heart rate. - Mild methemoglobinemia: reversible with monitoring.

Serious or Rare Side Effects: - Severe hypotension: can lead to organ hypoperfusion. - Cyanide toxicity: accumulation with prolonged high‑dose infusions. - Severe methemoglobinemia: may impair oxygen delivery. - Cardiac arrhythmias: including ventricular ectopy. - Renal impairment: worsening kidney function. - Anaphylactic reactions: rare but possible.

What precautions apply to Sodium Nitroprusside Dihydrate?

Careful monitoring and specific safeguards are required when administering Nipruss.

Blood pressure monitoring: continuous invasive measurement is required during infusion. Cyanide accumulation: limit duration and monitor plasma cyanide levels in prolonged use. Renal or hepatic impairment: adjust infusion rate and monitor organ function. Pregnancy and lactation: use only if benefits outweigh potential risks. Drug incompatibility: do not mix with strong acids or bases; use a dedicated line. Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Sodium Nitroprusside Dihydrate interact with?

Sodium nitroprusside can interact with several agents, altering its safety profile.

Major Interactions (Avoid): - Thiopental: additive hypotensive effect. - Other vasodilators (nitroglycerin, hydralazine): risk of profound hypotension. - MAO inhibitors: may potentiate blood‑pressure lowering. - Cyanide donors (sodium nitrite): increase cyanide load.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance blood‑pressure reduction. - Beta‑blockers: may mask reflex tachycardia. - ACE inhibitors/ARBs: additive effect on blood pressure.

Frequently asked questions

What is Nipruss used for?+
Nipruss contains sodium nitroprusside and is indicated for rapid blood‑pressure control in hypertensive emergencies, for achieving controlled hypotension during surgical procedures, and for managing acute heart failure when severe hypertension is present. These uses rely on its ability to produce immediate vasodilation.
How does Sodium Nitroprusside work?+
Sodium nitroprusside releases nitric oxide in the bloodstream. The nitric oxide activates soluble guanylate cyclase in vascular smooth‑muscle cells, increasing cyclic GMP, which relaxes arterial and venous smooth muscle. This results in a swift reduction of systemic vascular resistance and a rapid fall in arterial pressure.
What is the usual dose of Nipruss?+
The dose of Nipruss is individualized by the prescribing clinician. It is administered as an intravenous infusion, and the rate is titrated to the patient’s blood‑pressure response while maintaining continuous hemodynamic monitoring. Exact dosing regimens are determined case‑by‑case.
Is Nipruss safe in pregnancy or breastfeeding?+
Safety data for sodium nitroprusside in pregnancy and lactation are limited. It should only be used when the potential maternal benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.
How do I order Nipruss from GNH USA?+
To order Nipruss, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.
How does Nipruss compare with other antihypertensive agents?+
Compared with other rapid‑acting antihypertensives such as nitroglycerin or labetalol, sodium nitroprusside produces a more immediate and controllable drop in both arterial and venous pressure. However, it requires careful monitoring for cyanide accumulation, whereas some alternatives have longer half‑lives and different side‑effect profiles.
How should Nipruss be stored and handled?+
Nipruss should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before use, allow the product to reach room temperature if required, and handle with aseptic technique to maintain sterility.
How is Nipruss administered?+
Nipruss is given by intravenous infusion. The solution is diluted in a compatible carrier fluid and administered through a dedicated line using an infusion pump. Continuous arterial pressure monitoring is essential, and the infusion rate is adjusted based on real‑time blood‑pressure readings.
What are the most serious risks to watch for with Nipruss?+
The most critical risks include severe hypotension leading to organ hypoperfusion, cyanide toxicity from prolonged high‑dose infusions, and significant methemoglobinemia that can impair oxygen delivery. Prompt recognition and appropriate monitoring are required to mitigate these hazards.
Who should not use Nipruss?+
Nipruss is contraindicated in patients with known hypersensitivity to sodium nitroprusside, severe anemia, or those with significant cyanide metabolism disorders. Caution is also advised in patients with uncontrolled heart failure, severe renal or hepatic impairment, and in pregnant or breastfeeding women unless absolutely necessary.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Sodium Nitroprusside Dihydrate
Route
Intravenous Use
Manufacturer
Oresund Pharma Aps
Origin
EU

Related products

Nipruss

Nipruss

Sodium Nitroprusside Dihydrate

Altamedics Gmbh
EU
Nipruss

Nipruss

Sodium Nitroprusside Dihydrate

Altamedics Gmbh
EU
Nipruss

Nipruss

Sodium Nitroprusside Dihydrate

Oresund Pharma Aps
EU
Nipruss

Nipruss

Sodium Nitroprusside Dihydrate

Oresund Pharma Aps
EU